AAPL 206.655 1.0044% MSFT 384.86 2.7965% NVDA 106.185 3.3833% GOOGL 158.72 2.1693% GOOG 160.73 1.9084% AMZN 185.5673 2.7504% META 530.91 2.0451% AVGO 187.43 5.9465% BRK-A 795500.0 0.8495% BRK-B 530.135 0.6312% LLY 855.05 3.0901% TSLA 255.535 1.9123% TSM 163.78 3.783% V 336.305 0.5787% JPM 243.935 1.2683% UNH 426.3 -0.3879% NVO 62.61 2.137% WMT 95.78 0.8635% LVMUY 113.69 1.6632% XOM 108.77 1.3039%
Last update at 2025-04-23T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -27.17000M | -31.66200M | -17.90500M | -15.23700M | -11.37100M |
| Minority interest | - | - | - | - | - |
| Net income | -21.57500M | -31.71000M | -17.63000M | -14.84500M | -11.37100M |
| Selling general administrative | 16.18M | 13.26M | 8.27M | 5.81M | 5.05M |
| Selling and marketing expenses | 14.95M | 17.09M | 8.84M | 9.64M | 5.64M |
| Gross profit | 4.32M | 3.06M | 1.24M | 1.20M | -0.08900M |
| Reconciled depreciation | 0.26M | 0.30M | 0.27M | 0.33M | 0.68M |
| Ebit | -32.76500M | -32.59500M | -18.24600M | -15.61100M | -12.00800M |
| Ebitda | -38.23700M | -32.29300M | -17.98100M | -15.27800M | -11.33300M |
| Depreciation and amortization | -5.47200M | 0.30M | 0.27M | 0.33M | 0.68M |
| Non operating income net other | - | - | 0.07M | - | - |
| Operating income | -32.76500M | -32.59500M | -17.98100M | -15.27800M | -11.33300M |
| Other operating expenses | 40.95M | 39.41M | 22.63M | 19.82M | 14.39M |
| Interest expense | 0.02M | -0.04800M | 0.00000M | 0.06M | 0.02M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | 0.01000M | 0.06M | 0.02M |
| Net interest income | 0.02M | -0.04800M | 0.01000M | 0.06M | -0.02200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -5.59500M | 0.05M | -0.27500M | -0.39200M | -0.03800M |
| Total revenue | 8.18M | 6.81M | 4.65M | 4.54M | 3.05M |
| Total operating expenses | 37.08M | 35.66M | 19.22M | 16.47M | 11.24M |
| Cost of revenue | 3.87M | 3.75M | 3.42M | 3.34M | 3.14M |
| Total other income expense net | 5.59M | 0.93M | 0.08M | 0.04M | -0.01600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -27.17000M | -31.66200M | -17.90500M | -15.23700M | -11.37100M |
| Net income applicable to common shares | -27.17000M | -31.66200M | -17.90500M | -15.23700M | -11.37100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 6.26M | 17.37M | 41.08M | 19.61M | 13.83M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.00M | 1.44M | 1.62M | 1.08M | 0.76M |
| Total liab | 8.63M | 10.64M | 10.91M | 9.89M | 5.09M |
| Total stockholder equity | -2.36500M | 6.73M | 30.17M | 9.72M | 8.74M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2.86M | 3.65M | 5.30M | 3.62M | 0.04M |
| Common stock | 0.01M | 0.12M | 0.11M | 0.10M | 0.10M |
| Capital stock | - | 0.12M | 0.11M | 0.10M | 0.10M |
| Retained earnings | -518.30300M | -498.89800M | -471.72800M | -440.06600M | -422.16100M |
| Other liab | - | 2.28M | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.41M | 0.26M | 0.00042M | 0.07M |
| Cash | 2.60M | 13.31M | 37.18M | 16.63M | 11.70M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 5.12M | 5.78M | 7.84M | 6.40M | 3.98M |
| Current deferred revenue | - | - | - | - | 2.59M |
| Net debt | 0.26M | -9.47500M | -33.07300M | -11.51200M | -10.41100M |
| Short term debt | 0.99M | 1.24M | 1.04M | 1.63M | 0.19M |
| Short long term debt | - | 1.17M | 0.98M | 1.61M | 0.19M |
| Short long term debt total | 2.85M | 3.83M | 4.11M | 5.12M | 1.29M |
| Other stockholder equity | 515.93M | 505.50M | 501.79M | 449.68M | 430.80M |
| Property plant equipment | - | 0.65M | 0.81M | 0.99M | 0.35M |
| Total current assets | 5.28M | 16.31M | 40.01M | 18.60M | 13.41M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 6.73M | 30.17M | 9.72M | 8.74M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1.46M | 1.25M | 1.03M | 0.86M | 0.92M |
| Long term debt | - | 2.31M | 2.72M | 3.08M | 1.10M |
| Inventory | 0.23M | 0.32M | 0.17M | 0.03M | 0.03M |
| Accounts payable | 1.26M | 0.88M | 1.50M | 1.15M | 1.16M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | -2.38100M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.10M | 0.10M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -440.06600M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.03M | 0.41M | 0.26M | 0.01M | 0.07M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.98M | 1.06M | 1.07M | 1.00M | 0.42M |
| Capital lease obligations | - | 0.35M | 0.41M | 0.43M | - |
| Long term debt total | - | - | - | 3.08M | 1.10M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.23200M | -0.18400M | -0.49000M | -0.13200M | -0.11300M |
| Change to liabilities | 0.00000M | 2.25M | 1.59M | 0.97M | 0.38M |
| Total cashflows from investing activities | - | -0.18400M | -0.49000M | -0.13200M | -0.11300M |
| Net borrowings | - | -0.19800M | 2.81M | -0.18900M | -0.21400M |
| Total cash from financing activities | 8.54M | 48.38M | 20.15M | 15.44M | 13.30M |
| Change to operating activities | - | -0.54800M | -0.31900M | -0.20900M | -0.09200M |
| Net income | -27.17000M | -31.66200M | -17.90500M | -15.23700M | -11.37100M |
| Change in cash | -23.87300M | 20.80M | 4.93M | 2.34M | 3.82M |
| Begin period cash flow | 37.43M | 16.63M | 11.70M | 9.36M | 5.54M |
| End period cash flow | 13.56M | 37.43M | 16.63M | 11.70M | 9.36M |
| Total cash from operating activities | -32.18500M | -27.39500M | -14.73400M | -12.96600M | -9.36700M |
| Issuance of capital stock | 9.00M | 48.23M | 10.64M | 13.52M | 13.49M |
| Depreciation | 0.26M | 0.30M | 0.27M | 0.33M | 0.68M |
| Other cashflows from investing activities | - | - | - | 0.00100M | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.14200M | -0.14400M | -0.00500M | 0.07M | 0.01000M |
| Change to account receivables | -0.21800M | -0.16200M | 0.06M | -0.13800M | -0.08100M |
| Sale purchase of stock | - | - | 17.34M | 15.63M | 13.52M |
| Other cashflows from financing activities | -0.19500M | 0.34M | 9.70M | 2.11M | 4.53M |
| Change to netincome | - | 2.57M | 1.58M | 1.25M | 1.11M |
| Capital expenditures | 0.23M | 0.18M | 0.49M | 0.13M | 0.11M |
| Change receivables | - | - | 0.06M | - | - |
| Cash flows other operating | - | - | -0.29300M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 4.93M | - | - |
| Change in working capital | -2.55100M | 1.39M | 1.33M | 0.69M | 0.22M |
| Stock based compensation | 2.68M | 3.54M | 1.55M | 1.19M | 1.10M |
| Other non cash items | -5.40400M | 0.04M | 0.03M | 0.05M | 0.01M |
| Free cash flow | -32.41700M | -27.57900M | -15.22400M | -13.09900M | -9.48000M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AWH Aspira Womens Health Inc |
-0.0005 1.85% | 0.03 | - | - | 1.36 | 5.02 | 1.36 | -1.0792 |
| TMO Thermo Fisher Scientific Inc |
-9.525 2.21% | 422.12 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.26 0.13% | 196.05 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
1.18 1.12% | 106.17 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
10.26 2.40% | 436.88 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
Building III, Austin, TX, United States, 78738
| Name | Title | Year Born |
|---|---|---|
| Ms. Valerie Barber Palmieri | Exec. Chairwoman | 1961 |
| Ms. Nicole Sandford CPA | Pres, CEO & Director | 1970 |
| Ms. Marlene McLennan | Interim CFO and Interim Principal Financial & Accounting Officer | 1970 |
| Dr. Ryan Phan M.D., Ph.D. | Chief Operating & Scientific Officer | NA |
| Mr. Sean Rowe | Sr. VP of Technology | NA |
| Ms. Minh Merchant | Gen. Counsel & Corp. Sec. | NA |
| Ms. Emily Granger | Director of Marketing | NA |
| Mr. Gregory Richard | Sr. VP of Market & Bus. Devel. | 1967 |
| Dr. Charles J. Dunton M.D. | Interim Chief Medical Officer | NA |
| Mr. Michael J. Newton | Sr. VP of Commercial | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...